AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30

AYTU BIOPHARMA, INC

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 22, 2026

$1.96−0.08 (-3.92%)

Close on Oct 19, 2026

Market cap: $37.82M
P/E (TTM): –
Dividend yield: –

AYTU BIOPHARMA, INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30	FY 2019 2019-06-30	FY 2018 2018-06-30	FY 2017 2017-06-30	FY 2016 2016-06-30	FY 2015 2015-06-30	FY 2013 2013-08-31	FY 2012 2012-08-31	FY 2011 2011-08-31	FY 2010 2010-08-31	FY 2009 2009-08-31	FY 2008 2008-08-31	FY 2007 2007-08-31	FY 2006 2006-08-31
Revenue	58	66	65	107	97	66	28	7.32	3.66	3.22	2.56	0.26	0.00	0.00	–	–	–	–	–	–
Cost of Revenue	21	21	16	41	44	36	8.28	2.20	2.05	1.42	0.96	0.09	–	–	–	–	–	–	–	–
Gross Profit	37	46	49	67	52	29	19	5.12	1.61	1.80	1.61	0.17	–	–	–	–	–	–	–	–
Research & Development	0	1.33	2.77	4.10	13	5.62	1.72	0.59	0.17	0.96	6.13	3.22	–	–	–	–	–	–	–	–
Selling, General & Admin	43	38	42	70	70	56	35	19	18	17	8.52	3.98	–	–	–	–	–	–	–	–
Selling & Marketing	23	21	22	41	39	30	11	–	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	19	17	20	29	31	26	20	–	–	–	–	4.38	0.03	0.03	0.08	–	–	–	–	–
Advertising Expenses	–	–	4.90	17	14	15	4.70	0	–	–	–	–	–	0.00	0.00	–	–	–	–	–
Operating Expenses	45	54	51	84	162	88	40	24	23	23	24	7.89	–	–	–	–	–	–	–	–
Total Costs & Expenses	–	–	–	–	–	–	–	–	–	–	–	–	0.05	0.06	0.13	–	–	–	–	–
Operating Income	-8.32	-7.83	-1.59	-17	-110	-59	-21	-17	-20	-20	-22	-7.63	-0.05	-0.06	-0.13	–	–	–	–	–
Interest Expense	1.90	3.70	5.06	4.96	0.90	–	2.61	0.54	0.75	2.53	5.49	0.11	0.00	0.00	0.00	–	–	–	–	–
Other Non-Operating Income	0.71	-0.51	0.87	0.18	1.02	0.84	7.51	-10	9.51	-2.38	-6.48	-0.11	0.00	0.00	0.00	–	–	–	–	–
Merger & Restructuring Charges	0	2.10	2.16	0	0	4.89	0.67	–	–	0.00	0	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	0	8.26	0	5.71	75	13	0.20	0	1.86	1.27	7.50	0	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	-0.06	-0.97	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	0.50	0	0.10	0.10	-0.10	0	–	–	0.43	0	–	–	–	–	–	–	–	–	–
Pretax Income	-14	-14	-10	-17	-109	-58	-14	–	–	–	-28	-7.75	–	–	–	–	–	–	–	–
Income Tax Expense	0.02	0.44	2.14	0	-0.11	0.26	0	0	0	0	0	-0.02	–	–	–	–	–	–	–	–
Income from Continuing Operations	-14	-14	-13	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income from Discontinued Operations	0	0.62	-3.32	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	-17	-109	-58	-14	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-14	-14	-16	-17	-109	-58	-14	-27	-10	-23	-28	-7.72	-0.06	-0.06	-0.14	-0.06	-0.06	-0.06	-0.05	-0.07
EPS (Basic)(per share)	-1.16	-2.16	-2.86	-5.11	-74.01	-69.60	-60.20	-696.00	-3,062.00	-193,200.00	-1,294,800.00	-805,600.00	-54,400.00	-54,400.00	-163,200.00	–	–	–	–	–
EPS (Diluted)(per share)	–	–	–	-5.11	-74.01	-69.60	-60.20	-696.00	-3,062.00	-193,200.00	-1,294,800.00	-805,600.00	-54,400.00	-54,400.00	-163,200.00	–	–	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	12	6.28	5.54	3.34	1.47	0.84	0.23	0.04	0.00	0.00	0.00	0.00	0.00	0.00	–	–	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	12	6.28	5.54	3.34	1.47	0.84	0.23	0.04	0.00	0.00	0.00	0.00	0.00	0.00	–	–	–	–	–	–
EBITDA	-4.39	-2.45	5.13	-8.25	-100	-50	-15	-14	-17	-16	-21	-7.51	0.01	0.00	–	–	–	–	–	–
Net Interest Income	–	–	–	–	–	–	–	–	–	–	–	-0.11	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 64.0%
Operating margin: -14.4%
Net margin: -24.8%
Return on equity, FY2026: -52.6%

Financial strength

Current ratio: 1.13
Debt to equity: 0.31
Debt to assets: 10.4%
Cash to current liabilities: 48.1%

Valuation

P/E ratio: –
Price to sales: 0.66
Price to book: 1.07
Dividend yield: –